New partnership to explore combination therapies for cancer treatment
- Antengene teams up with Junshi Biosciences for cancer research
- Focus on combining ATG-037 and JS207 therapies
- Collaboration aims to enhance treatment for cancer patients
Antengene has announced a collaboration with Junshi Biosciences to investigate the potential synergistic effects of their cancer treatments. This partnership will focus on the oral CD73 inhibitor ATG-037 in combination with Junshi's JS207, a PD-1 and VEGF bispecific antibody. The aim is to enhance cancer treatment outcomes for patients undergoing therapy.
The clinical collaboration will include studies assessing the safety and efficacy of the combined therapies. By leveraging each company's research strengths, the collaboration seeks to determine how these treatments can work together to improve patient response rates. This initiative highlights a growing trend in cancer therapy research focused on combination treatments.
The investigation into these novel treatments underscores the importance of ongoing research in the field of oncology. With a shared goal of advancing patient care, Antengene and Junshi Biosciences are committed to exploring innovative approaches that could offer new hope for cancer patients.
